Bimekizumab Dosage

Medically reviewed by Drugs.com. Last updated on Jan 8, 2024.

Usual Adult Dose for Plaque Psoriasis

320 mg subcutaneously once at weeks 0, 4, 8, 12, 16, and then every 8 weeks thereafter.

Comments:

• Administer 320 mg injection as 2 subcutaneous injections of 160 mg each.
• For patients weighing 120 kg or more, consider administering 320 mg subcutaneously once every 4 weeks after week 16.

Use: For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For subcutaneous use only.
• For single use in one patient only. Discard residue.
• Suitable areas for injection include the thigh, abdomen, and upper arm. Injection sites should be rotated, and injections should not be given into psoriasis plaques or areas where the skin is tender, bruised, erythematous, or indurated.
• The recommended dose should be administered as 2 subcutaneous injections of 160 mg each.
• Health care professionals should provide proper training to patients and/or caregivers on injection techniques. Patients may self-inject after training.
• If a dose is missed, administer the dose as soon as possible. Thereafter, resume doing every 4 weeks.

Storage requirements:

• Store in the refrigerator 2C to 8C (36F to 46F); do not freeze.
• Keep the pre-filled pen in the outer carton to protect from light; do not shake.
• Once removed from the refrigerator, the pre-filled pen may be stored at room temperature (up to 25C) for a maximum of 30 days or by the expiry date printed on the container, whichever occurs first.

General:

• This drug is intended for use under the guidance and supervision of a physician experienced in diagnosing and treating conditions for which it is indicated.
• Contact the Organization of Teratology Information Specialists (OTIS) Autoimmune Disease Study for pregnancy registry at http://mothertobaby.org/pregnancy-studies/ or call 1-877-311-8972.

Monitoring:

• Infection: Active infections (prior to and during therapy)
• Hepatic: Liver function, alkaline phosphatase, and bilirubin (prior to and during therapy)
• Immunization: Age-appropriate vaccinations (prior to initiating therapy)
• Psychiatric: Suicidal Ideation/behavior (prior to and during therapy)
• Respiratory: Tuberculosis (prior to initiating therapy)

Patient advice:

• Read the FDA-approved patient labeling (Medication Guide) and Instructions for Use.
• Complete proper training with your health care provider prior to self-administering subcutaneous injections.
• Seek immediate medical attention if you experience symptoms of serious hypersensitivity reactions.
• Promptly seek medical attention if you experience suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes. Call the National Suicide and Crisis Lifeline at 988.
• Vaccination with live vaccine is not recommended during treatment and immediately prior to or after treatment with this drug.
• Contact your healthcare provider immediately if you experience:
• Signs of infection such as fever
• Symptoms suggestive of tuberculosis such as fever, cough, or difficulty breathing
• Symptoms suggestive of liver injury such as unexplained rash, nausea, vomiting, abdominal pain, fatigue, weight loss, or jaundice and/or dark urine
• A pregnancy registry is available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer